0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Hodgkin Lymphoma Treatment Market by Treatment Type, Disease Stage, Treatment Line, Molecule Type, Patient Age - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715559
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Hodgkin Lymphoma Treatment Market is entering a phase of important transformation, characterized by evolving care models, novel therapies, and increasing operational complexity. Senior decision-makers are navigating an environment defined by innovation, regulatory shifts, and the persistent focus on optimizing patient outcomes.

Market Snapshot: Hodgkin Lymphoma Treatment Market

The global Hodgkin Lymphoma Treatment Market grew from USD 1.31 billion in 2024 to USD 1.43 billion in 2025, and is projected to expand at a CAGR of 9.28%, reaching USD 2.23 billion by 2030. This trajectory reflects strong demand across demographics, ongoing advances in immunotherapy and targeted modalities, and a competitive landscape shaped by regulatory and cost considerations. Influences such as shifts in patient populations, technology integration, and emerging market participation inform near- and mid-term strategy for industry leaders.

Scope & Segmentation

This report provides a comprehensive assessment of market trends, segment dynamics, and competitive structure:

  • Treatment Types: Chemotherapy (including ABVD, BEACOPP, liposomal formulations), Immunotherapy (PD-1 inhibitors such as epacadostat, nivolumab, pembrolizumab), Radiotherapy (adaptive, involved-field, proton modalities), Targeted Therapy (CD30-directed options like brentuximab vedotin, bispecific constructs)
  • Disease Stages: Early Stage (Stage I, II) and Advanced Stage (Stage III, IV)
  • Treatment Lines: First, second, and third line settings
  • Molecule Types: Monoclonal antibodies (CD30, PD-1 inhibitors); Small molecule inhibitors (HDAC inhibitors, next-generation compounds)
  • Patient Age Cohorts: Adult, geriatric, pediatric
  • Regional Coverage: Americas (United States, Canada, Mexico, major South American economies), Europe, Middle East & Africa (comprehensive national coverage), Asia-Pacific (including China, India, Japan, Southeast Asian markets)
  • Technology Integration: Genomics, artificial intelligence for stratification, digital biomarkers, advanced drug delivery (liposomal), and adaptive radiotherapy solutions
  • Industry Players Tracked: Leading pharmaceutical innovators, mid-sized biotechnology firms, and contract manufacturing organizations

Key Takeaways for Senior Decision-Makers

  • Immuno-oncology and targeted therapies are steadily supplanting traditional regimens, especially in refractory and high-risk cohorts, impacting both clinical practice and long-term survivorship models.
  • Advances in AI-driven molecular profiling and digital biomarker integration enable improved patient stratification, influencing both trial design and commercial rollout strategies.
  • Regional differentiation remains critical: developed markets support rapid adoption of innovative modalities, while reimbursement disparities and access constraints persist in emerging regions, shaping tailored go-to-market plans.
  • The competitive ecosystem rewards portfolio diversity and agile response to regulatory evolution. Strategic alliances and local manufacturing collaborations help accelerate adaptation and mitigate operational risk.
  • Extended focus on long-term safety, outcome tracking, and survivorship is influencing how value propositions are constructed and communicated to payers, providers, and patients.

Tariff Impact: Navigating Supply Chain Challenges

With the implementation of increased US tariffs in 2025, the Hodgkin Lymphoma Treatment Market experienced ripple effects across logistics and procurement. Rising costs for pharmaceutical ingredients and specialized equipment placed pressure on early-stage biotech firms, sometimes delaying trial milestones or altering sourcing strategies. Larger entities adjusted pricing models and sought manufacturing partnerships closer to key markets to maintain accessibility, while strategic stockpiling and supply chain agility became priorities.

Methodology & Data Sources

This analysis employs qualitative interviews with sector experts, including oncologists and regulatory figures, complemented by data from peer-reviewed research, proprietary clinical databases, and public filings. Segmentation followed a bottom-up mapping of modalities and region, while competitive analysis leveraged patent reviews, collaboration announcements, and clinical tracking. All findings were validated through expert peer review and multi-source triangulation.

Why This Report Matters

  • Equips decision-makers with granular insights into evolving therapy models, regulatory changes, and competitive positioning, supporting evidence-based strategy.
  • Enables benchmarking against best-in-class innovation and supply chain adaptation, particularly in the face of tariff volatility and new technology adoption.

Conclusion

Hodgkin lymphoma treatment is advancing through continuous therapeutic innovation, new care models, and dynamic regulatory conditions. With comprehensive coverage across segments, geographies, and value chain participants, this report informs forward-looking decisions and sustainable growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hodgkin Lymphoma Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Abvd Regimen
8.2.2. Beacopp Regimen
8.2.3. Liposomal Formulations
8.3. Immunotherapy
8.3.1. Pd-1 Inhibitors
8.3.1.1. Epacadostat Inhibitors
8.3.1.2. Nivolumab
8.3.1.3. Pembrolizumab
8.4. Radiotherapy
8.4.1. Adaptive Radiotherapy
8.4.2. Involved-Field Radiotherapy
8.4.3. Proton Radiotherapy
8.5. Targeted Therapy
8.5.1. Cd30 Targeted Therapy
8.5.1.1. Bite Therapies
8.5.1.2. Brentuximab Vedotin
9. Hodgkin Lymphoma Treatment Market, by Disease Stage
9.1. Introduction
9.2. Advanced Stage
9.2.1. Stage III
9.2.2. Stage IV
9.3. Early Stage
9.3.1. Stage I
9.3.2. Stage II
10. Hodgkin Lymphoma Treatment Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line
11. Hodgkin Lymphoma Treatment Market, by Molecule Type
11.1. Introduction
11.2. Monoclonal Antibodies
11.2.1. Cd30 Directed Antibodies
11.2.1.1. Brentuximab Vedotin
11.2.1.2. Next Generation Antibodies
11.2.2. Pd-1 Inhibitors
11.2.2.1. Nivolumab
11.2.2.2. Pembrolizumab
11.3. Small Molecules
11.3.1. Histone Deacetylase Inhibitors
11.3.1.1. Next Generation Hdac Inhibitors
11.3.1.2. Romidepsin
11.3.1.3. Vorinostat
12. Hodgkin Lymphoma Treatment Market, by Patient Age
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
13. Americas Hodgkin Lymphoma Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hodgkin Lymphoma Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hodgkin Lymphoma Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Takeda Pharmaceutical Company Limited
16.3.2. Bristol-Myers Squibb Company
16.3.3. Merck & Co., Inc.
16.3.4. Gilead Sciences, Inc.
16.3.5. Novartis AG
16.3.6. Roche Holding AG
16.3.7. Johnson & Johnson
16.3.8. Pfizer Inc.
16.3.9. Seagen Inc.
16.3.10. Kite Pharma, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HODGKIN LYMPHOMA TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. HODGKIN LYMPHOMA TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ABVD REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BEACOPP REGIMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EPACADOSTAT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADAPTIVE RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INVOLVED-FIELD RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PROTON RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BITE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STAGE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BRENTUXIMAB VEDOTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NEXT GENERATION HDAC INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROMIDEPSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY VORINOSTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 103. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 106. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 107. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 108. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 109. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 110. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 111. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 112. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 113. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 114. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 115. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 116. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 117. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 118. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 119. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 120. CANADA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 121. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 122. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 123. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 124. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 126. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 127. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 128. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 130. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 131. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 132. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 134. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 135. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 137. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 154. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 210. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 212. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 213. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 214. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 215. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 216. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 217. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 218. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 219. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 220. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 221. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 222. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 223. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 224. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 225. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 226. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 227. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 228. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 229. GERMANY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 232. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 233. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 234. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 235. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 236. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 237. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 238. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 239. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 240. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 241. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 242. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 243. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 244. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 245. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 246. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 247. FRANCE HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 262. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 264. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 265. RUSSIA HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 266. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 268. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 269. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 270. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 271. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 272. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 273. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 274. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 275. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 276. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 277. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 278. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 279. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 280. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 281. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 282. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 283. ITALY HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 284. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 285. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 286. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 287. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 288. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 289. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 290. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 291. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
TABLE 292. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 293. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 294. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT LINE, 2018-2030 (USD MILLION)
TABLE 295. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 296. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 297. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 DIRECTED ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 298. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 299. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 300. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 301. SPAIN HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PD-1 INHIBITORS, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CD30 TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DISEASE ST

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Hodgkin Lymphoma Treatment market report include:
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.
  • Novartis AG
  • Roche Holding AG
  • Johnson & Johnson
  • Pfizer Inc.
  • Seagen Inc.
  • Kite Pharma, Inc.

Table Information

This website uses cookies to ensure you get the best experience. Learn more